<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02059668</url>
  </required_header>
  <id_info>
    <org_study_id>STR- HNprädBio-2013</org_study_id>
    <nct_id>NCT02059668</nct_id>
  </id_info>
  <brief_title>Observational Study on Biomarkers in Head and Neck Cancer (HNprädBio)</brief_title>
  <acronym>HNprädBio</acronym>
  <official_title>Observational Study on Biomarkers in Head and Neck Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität Dresden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this clinical research project is to validate the prognostic impact of potential
      biomarkers on loco-regional control of locally advanced head and neck cancer after definitive
      or adjuvant radiochemotherapy. The treatment is equal to the standard of care.

      Potential biomarkers from a previous retrospective study will be validated in this
      prospective study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:

      Primary: Evaluation of local-regional recurrence- free survival after two years of patients
      with locally advanced head and neck cancer who received definitive or adjuvant
      radiochemotherapy.

      Secondary: Evaluation of disease-free -survival, metastases-free and overall survival after
      two years, of patients with locally advanced head and neck cancer.

      Outline: This is a multicenter observational study. The treatment is based on the center
      specific standard of care. The total dose will be between 69 and 73 Gy (definitive treatment)
      and 63 and 66 Gy (adjuvant treatment), the chemotherapy will be cisplatin- based.

      The aim of the analysis is to validate the prognostic impact of potential biomarkers on
      loco-regional control. This will lead to the definition of risk groups and stratification of
      patients and will help to individualize radiotherapy prescription in future trials.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>local recurrence free survival</measure>
    <time_frame>after 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>disease-free survival</measure>
    <time_frame>after 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>metastases-free survival</measure>
    <time_frame>after 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>after 2 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">550</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Biomarker analyses head &amp; neck cancer tissue, blood specimen</arm_group_label>
    <description>Validation of prognostic biomarkers for local tumor control in definitive and adjuvant treatment of head and neck cancer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Biomarker analyses head &amp; neck cancer tissue, blood specimen</intervention_name>
    <description>For biomarker analyses, tumor tissues from previous biopsies and surgery and blood specimens taken during treatment at the treating institution will be used.</description>
    <arm_group_label>Biomarker analyses head &amp; neck cancer tissue, blood specimen</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      if possible fresh-frozen tumor tissues, blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with the diagnosis locally advanced squamous cell carcinoma of the head and neck
        area
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Primary radiochemotherapy:

          -  Patients with locally advanced squamous cell carcinoma of the oral cavity, oropharynx
             or hypopharynx

          -  Stage III or IV without distant metastases

          -  Patient is able to participate in regular tumor follow-up care

          -  planned irradiation dose 69-72 Gy

          -  planned overall treatment time 38-54 days

          -  written informed consent of the patient

          -  general condition according to WHO 0-2

          -  planned simultaneous chemotherapy with cisplatin (cumulative planned total dose
             minimum 180 mg/m2 body surface, divided in several separately doses)

        Adjuvant radiochemotherapy:

          -  Patients with locally advanced squamous cell carcinoma of the oral cavity, oropharynx
             or hypopharynx

          -  surgery, existence of one or more of the following risk factors for local recurrence:

          -  extracapsular growth of a minimum of one lymph node metastasis

          -  R1 resection

          -  pT4 tumor and more than 3 affected lymph nodes

          -  Patient is able to participate in regular tumor follow-up care

          -  planned irradiation dose 63-66 Gy

          -  planned overall treatment time 44-48 days

          -  planned simultaneous chemotherapy with cisplatin (cumulative planned total dose
             minimum 200 mg/m2 body surface, divided in several separately doses)

          -  written informed consent of the patient

          -  general condition according to WHO 0-2

          -  time since last surgery &lt;56 days (8 weeks)

        Exclusion Criteria:

        Primary radiochemotherapy:

          -  distant metastasis

          -  contraindication against a cisplatin-based chemotherapy

          -  planned total irradiation dose &lt;69 Gy and &gt;72 Gy

          -  planned overall treatment time &gt;54 days or &lt;38 days

          -  Patient is incapable of giving consent

          -  previous radiotherapy in the head and neck area, if there is a risk for overlapping of
             the irradiation areas

          -  other tumor diseases, which currently need a treatment or probably within the next two
             years or which influence the prognosis of the patient

          -  tumor-independent diseases or conditions which reduce the survival probability of the
             patient to &lt;2 years or which affect the follow-up over 2 years

          -  no written informed consent

          -  induction chemotherapy

          -  pregnancy or lactation

        Adjuvant radiochemotherapy:

          -  distant metastasis

          -  contraindication against a cisplatin-based chemotherapy

          -  planned total irradiation dose &lt; 63 Gy or &gt; 66 Gy

          -  planned overall treatment time &gt; 48 days or &lt; 44 day

          -  Patient is incapable of giving consent

          -  previous radiotherapy in the head and neck area, if there is a risk for overlapping of
             the irradiation areas

          -  other tumor diseases, which currently need a treatment or probably within the next two
             years or which influence the prognosis of the patient

          -  tumor-independent diseases or conditions which reduce the survival probability of the
             patient to &lt;2 years or which affect the follow-up over 2 years

          -  no written informed consent

          -  pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mechthild Krause, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dresden University of Technology, Universital Hospital Carl Gustav Carus, Department of Radiation Therapy and Radiation Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mechthild Krause, Prof.</last_name>
    <phone>+49 351 458 2238</phone>
    <email>str.studien@uniklinikum-dresden.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Prof. Anca-Ligia Grosu</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anca-Ligia Grosu, Prof.</last_name>
      <phone>+49 761 270 94610</phone>
      <email>anca.grosu@uniklinik-freiburg.de</email>
    </contact>
    <investigator>
      <last_name>Ana-Ligia Grosu, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prof. Jürgen Debus</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jürgen Debus, Prof.</last_name>
      <phone>+49 6221 / 56 82 01</phone>
      <email>Juergen.Debus@med.uni-heidelberg.de</email>
    </contact>
    <investigator>
      <last_name>Jürgen Debus, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prof. Daniel Zips</name>
      <address>
        <city>Tübingen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>72016</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Zips, Prof.</last_name>
      <phone>+49 7071/29-8 21 65</phone>
      <email>ROInfo@med.uni-tuebingen.de</email>
    </contact>
    <investigator>
      <last_name>Daniel Zips, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prof. Claus Belka</name>
      <address>
        <city>München</city>
        <state>Bavaria</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claus Belka, Prof.</last_name>
      <phone>+49 89 7095 4520</phone>
      <email>Claus.Belka@med.uni-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>Claus Belka, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prof. Stephanie Combs</name>
      <address>
        <city>München</city>
        <state>Bavaria</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Combs, Prof.</last_name>
      <phone>+49 89 41 40-45 02</phone>
      <email>radonk@lrz.tum.de</email>
    </contact>
    <investigator>
      <last_name>Stephanie Combs, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prof. Claus Rödel</name>
      <address>
        <city>Frankfurt</city>
        <state>Hesse</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claus Rödel, Prof.</last_name>
      <phone>+ 49 69 / 6301-5130</phone>
      <email>strahlentherapie@kgu.de</email>
    </contact>
    <investigator>
      <last_name>Claus Rödel, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prof. Martin Stuschke</name>
      <address>
        <city>Essen</city>
        <state>North Rhine-Westphalia</state>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Stuschke, Prof.</last_name>
      <phone>+49 201 / 723-23 20</phone>
      <email>martin.stuschke@uk-essen.de</email>
    </contact>
    <investigator>
      <last_name>Martin Stuschke, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prof. Mechthild Krause</name>
      <address>
        <city>Dresden</city>
        <state>Saxony</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mechthild Krause, Prof.</last_name>
      <phone>+49 351 458 2238</phone>
      <email>studien.str@uniklinikum-dresden.de</email>
    </contact>
    <investigator>
      <last_name>Mechthild Krause, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prof. Volker Budach</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Volker Budach, Prof.</last_name>
      <phone>+49 30 450 527 152</phone>
    </contact>
    <investigator>
      <last_name>Volker Budach, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Praxis für Strahlentherapie im Krankenhaus Dresden - Friedrichstadt</name>
      <address>
        <city>Dresden</city>
        <zip>01067</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Schreiber Andreas, Dr.</last_name>
      <email>strahlentherapie@khdf.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2014</study_first_submitted>
  <study_first_submitted_qc>February 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2014</study_first_posted>
  <last_update_submitted>November 3, 2017</last_update_submitted>
  <last_update_submitted_qc>November 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Technische Universität Dresden</investigator_affiliation>
    <investigator_full_name>Mechthild Krause</investigator_full_name>
    <investigator_title>Prof. Dr. Mechthild Krause</investigator_title>
  </responsible_party>
  <keyword>locally advanced head and neck cancer</keyword>
  <keyword>biomarkers</keyword>
  <keyword>definitive treatment</keyword>
  <keyword>adjuvant treatment</keyword>
  <keyword>radiochemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

